Lupin Q4 net profit up 18% at Rs 460 cr; FY21 profit at Rs 1,216 cr


Drug maker Lupin on Thursday reported an 18 per cent increase in its consolidated net profit at Rs 460 crore for the fourth quarter ended March 31, 2021, driven by robust sales across domestic and international markets.

The Mumbai-based company had reported a net profit of Rs 390 crore in the January-March quarter of 2019-20.

The company's total income from operations however declined to Rs 3,783 crore during the fourth quarter, as compared to Rs 3,846 crore in the corresponding period of FY20, Lupin Ltd said in a statement.

For the entire 2020-21 fiscal, the drug maker posted a consolidated net profit of Rs 1,216 crore. The company had reported a net loss of Rs 269 crore in 2019-20 financial year.

Total income from operations for the last fiscal stood at Rs 15,163 crore, as compared to Rs 15,375 crore in 2019-20.

"We are happy that the journey to sustain margin improvement continues, despite a challenging environment. On the back of a strong ramp-up of inline products and meaningful new product launches, we are confident of a solid growth trajectory and continued margin expansion," Lupin Ltd Managing Director Nilesh Gupta said.

Ensuring the safety of our employees while maintaining business continuity is a key priority at this time, he added.

The company said its board has recommended a dividend of Rs 6.5 per equity share of the face value of Rs 2 each aggregating to Rs 295 crore.

The drug firm noted that its capital expenditure for the fourth quarter stood at Rs 140 crore and for the full year (FY21) at Rs 628 crore.

Besides, the company's net debt as on March 31, 2021 stood at Rs 663 crore, it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel